There is no hazardous surcharge associated with this product.
There is no packaging charge associated with this product.
For Research Purposes only. Not for Personal use.
All compounds supplied are strictly intended for laboratory, research, analytical, and scientific use only. They are not meant for human consumption, therapeutic use, or any form of clinical application.
"Finn, R,, et al,: Breast Cancer Res,, 11, 5 (2009)"
Synonyms
Not available
Application Notes
Palbociclib (also known as compound number ) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
Purity by HPLC
Not less than 90 %
Hazard Compound
Refer MSDS for accurate information.
Overview
Palbociclib (also known as compound number ) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
